-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CIN-103 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CIN-103 in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CIN-103 in Irritable Bowel Syndrome Drug Details: CIN-103 is under development...
-
Product Insights
Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroparesis - Drugs In Development, 2023’, provides an overview of the Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Diabetic Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Diabetic Gastroparesis - Drugs In Development, 2023’, provides an overview of the Diabetic Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Irritable Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Irritable Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Irritable Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Renal Cell Carcinoma Drug Details: TAK-500 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-08 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-08 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-08 in Alzheimer's Disease Drug Details:BMND-08 (5-MeO-DMT) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CIN-103 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CIN-103 in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CIN-103 in Irritable Bowel Syndrome Drug Details:CIN-103 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Intestinal Schistosomiasis Vaccine in Intestinal Schistosomiasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Intestinal Schistosomiasis Vaccine in Intestinal Schistosomiasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Intestinal Schistosomiasis Vaccine in Intestinal SchistosomiasisDrug Details:Vaccine candidate (SchistoShield) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CIN-103
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CIN-103 Drug Details CIN-103 is under development for the treatment of diarrhea-predominant irritable bowel...